AttardLab
@AttardLab
Followers
1K
Following
54
Statuses
212
Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.
Joined January 2018
@AttardLab’s latest finding ( shows that autosome-defined relationship of metastases in lethal prostate cancer is also characterised by their AR gene architectures.
0
6
17
Find out @AttardLab’s latest publication ( showing that lethal prostate cancer progresses to lethal disease via a limited number (two or three) of dominant clones, each harbouring patient-specific androgen receptor gene architectures.
1
29
91
@AttardLab is proud to present its latest publication “Copy number architectures define treatment-mediated selection of lethal prostate cancer clones”🎉 in @NatureComms. Kudos to our team for their hard work! 👍
0
4
15
Exciting opportunity for computational biologist interested in studying drug resistance in prostate cancer
1
8
8
RT @marina_parry: Today is my last day @AttardLab @uclcancer! I’ve had a brilliant time. Been lucky enough to work with lovely people on in…
0
2
0
We’ve updated our website 🚨. More team members, more publications, more news! Check out for our refreshed look.
0
1
10
RT @Prof_Nick_James: Great all day meeting of the STAMPEDE Translational Research Group. So much great work: imaging, pathology, DNA & RNA…
0
12
0
Great opportunity for a trainee oncologist to join our team and become an expert on prostate cancer:
1
16
20
RT @AarmstrongDuke: Interesting genomic data from STAMPEDE particularly M0 patients. Can we avoid abiraterone safely in low genomic but hig…
0
20
0
It's a #STAMPEDE double bill kicking off the prostate proffered paper session at #ESMO22 with Gert presenting LBA62 and @marina_parry with 1358O. Hope to see you there, Sunday 11th, 8.30am Antibes auditorium.
0
17
61
Thrilled to share our 1st translational study looking at accumulation of copy number alterations & clinical progression in #STAMPEDE (. Thanks to funders @ProstateUK @CRUKresearch @PCF_Science @PCR_News & @EmilyGrist1 for driving this. Tweetorial to come!
0
32
75
Another important STAMPEDE paper. Tweetorial and link to paper 👇
5-year follow-up results from #STAMPEDEtrial reveal that adding docetaxel chemotherapy to the standard treatment helps patients with non-metastatic #ProstateCancer to live longer without their disease getting worse. Here’s a 🧵 of the results
0
5
13
RT @guconnectinfo: 1 week to go until our Experts Knowledge Share: 'Targeting Advanced #ProstateCancer with PARP inhibitors: Who, When and…
0
1
0
RT @Prof_Nick_James: 15 min podcast in conversation with @thelancet on the latest STAMPEDE results plus a commentary on the trial structure…
0
26
0
The #STAMPEDE trial is looking for a Clinical Trial Manager - a hugely important post. We look forward to working with the successful candidate as part of our translational projects. Apply before 21st Jan, link in tweet below👇
New Year, new job? We're looking for three Clinical Trial Managers to work on exciting, innovative clinical trials. Come and join our team! Apply by 21st Jan. Find out more with the link below
0
1
3
RT @scserendipity1: Well said Nick. A very good time to thank you for all the hard work you do behind the scenes to ensure that the study h…
0
3
0
RT @MRCCTU: @TheLancet @AttardLab @Prof_Nick_James @mattsydes Adding abiraterone to standard hormone therapy did increase severe side-effec…
0
5
0
STAMPEDE high risk: N1 or if N0, 2 of T3/4, GS 8-10 or PSA >39. Data currently only relevant to this pt group
1
5
27